c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. - Wikidata - wikimedia - TriplyDB

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases.

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases.

http://www.wikidata.org/entity/Q35199181

about

Targeting the hepatocyte growth factor-cMET axis in cancer therapy Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Prognostic value of c-Met in colorectal cancer: a meta-analysis Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets Biology of MET: a double life between normal tissue repair and tumor progression A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.5-Methylcytosine hydroxylation-mediated LINE-1 hypomethylation: a novel mechanism of proto-oncogenes activation in colorectal cancer?Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.Hsa-miR-574-5p negatively regulates MACC-1 expression to suppress colorectal cancer liver metastasis.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.Activating mutation in MET oncogene in familial colorectal cancer.Development of c-MET pathway inhibitors.MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors.Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma.Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met.Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay.c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication.Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.Expression and mutational analysis of MET in human solid cancers miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression.Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.Colorectal clinical trials: what is on the horizon?Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines.A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer.MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.Lentivirus-mediated RNA silencing of c-Met markedly suppresses peritoneal dissemination of gastric cancer in vitro and in vivo.

P2860

Q24606259-07951DAC-9394-4BD2-A47F-568FD0F28130 Q26751344-E1D80F7B-59BC-446F-AF92-C6DBCC7DC0D3 Q26860232-882B6A87-761A-4617-A02F-8A6875D69E13 Q28081193-A288B2B3-5FEE-446A-ADE9-329D1DC78465 Q28085247-49345A24-D423-48D2-9EE9-79F563300A68 Q33414632-CE133679-38E2-40E2-AF5B-374CE14FDFFC Q33670566-C964EEB4-7ED6-42BA-86B4-A371E4CCB99C Q33737789-9EC00CD6-FA56-499E-BD9A-7A619386224F Q33762682-491DF0CF-E6CD-424A-A1FC-4FCDA008CA94 Q33769429-CD640834-4731-4280-A8CC-68E0357705FE Q33769437-7AEB441F-CE06-4B38-8075-C9EBE1577278 Q34039577-5C969FFD-486F-4095-A16D-6CBA1A2E83F9 Q34198905-215795A8-163F-44B2-A99F-7434D4CBB63B Q34971893-C698D675-EEE2-4956-868C-743FE4185CBB Q35051660-B200AA25-3E03-42EA-BA6C-D3FEA0028652 Q35083852-44AD39EB-FBD5-4D15-9C56-E3393F1DB3E4 Q35212113-DBE8BAED-591D-46CB-84ED-46B51366F721 Q35222611-C5439F8D-D18B-48A2-93DD-7F78CC883A7E Q35235798-63F6B58D-B2CA-4148-8934-9B304DF023A4 Q35636713-D002EADC-3B73-4484-AAE1-B2A5D2C57C92 Q35713396-6998B647-AAD8-4BA2-9F95-D50B2BDDA4A3 Q35720171-291AC846-EE96-4226-99D7-6A145FCD3877 Q35804089-11EDCF98-2DF7-4521-B6E3-16251487FAAA Q35924247-39F7C0C2-7750-433C-BFC5-17ED8654B73E Q35982925-84592A63-4858-41FD-B0C4-90FA4DFBFB74 Q36118082-04268706-54E5-4690-B72A-3F76620768CD Q36352462-1ACD92E1-BC4A-4AC1-9570-94DC1AFFF6EB Q36361670-EAF38BA8-0FF1-498C-9E45-9F3BFE6CAF16 Q36713414-2D96DB9A-15E9-40ED-9E7F-B440D282E091 Q36843773-DA06A5FE-0FB7-4258-950A-210DEBB85253 Q36975055-3D207A62-1066-44E4-BFA5-9DB503ECDF76 Q36983766-858031B3-61AC-44CE-B062-B9DE7B3FA314 Q37133949-BF9E030D-4C71-48DB-ACF1-CB4BA64F258C Q37157958-AC7D3D03-5C08-48EE-99C1-3CC7CC14E2C7 Q37275734-DB23AF0B-84EA-4B33-9C25-16CBA6BEEA7C Q37352435-2B8E0053-D36E-439C-A097-AEF34370F4B6 Q37446488-4DEB5EC5-1D76-4A83-82CD-17C8B1593B51 Q37694731-6B7FB52C-209A-493B-A43B-1C68C77015F3 Q37702041-6BB4088A-7D17-47C7-AC6B-C517607B2DA2 Q37729958-D56E200E-2774-4CBD-87C1-F406B13AE623

P2860

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases.

http://www.wikidata.org/entity/Q35199181

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

c-Met gene amplification is as ...... l cancer and liver metastases.

@ast

c-Met gene amplification is as ...... l cancer and liver metastases.

@en

type

label

c-Met gene amplification is as ...... l cancer and liver metastases.

@ast

c-Met gene amplification is as ...... l cancer and liver metastases.

@en

prefLabel

c-Met gene amplification is as ...... l cancer and liver metastases.

@ast

c-Met gene amplification is as ...... l cancer and liver metastases.

@en

P1433

Q35199181-F0AC902F-34C7-4468-B190-D899FA21BB26

P1476

Q35199181-ECE5FCF5-0EDB-4A66-B11B-CBBA65AA7D5D

P2093

Q35199181-082AACA4-15B2-4BCD-8764-90F3CA7824DB

Q35199181-1419B1CE-4098-43A8-8808-70054E10904B

Q35199181-16E1F0B5-4833-4689-9760-F48EC7FCA904

Q35199181-1C90DB46-F6A6-4574-A694-CF141C611289

Q35199181-281856D1-6FC9-447D-89D3-0B04CC6392E2

Q35199181-52535270-727D-4E8E-A47A-6BE81B4BF378

Q35199181-934FBEB0-342B-48CB-B1E3-09FD1A9DDE5C

Q35199181-A8D6A330-2FE0-4EBD-8C9A-23659443B841

Q35199181-B4090FA5-FE55-4165-84BB-3EB22247D1F3

Q35199181-C7A16F4F-DB32-4565-9A10-3C55C83CDE7F

P2860

Q35199181-0CBB8677-0E81-4018-A97A-CCD2637918C2

Q35199181-0F481375-2510-4DC5-B690-B8DF1CA729A7

Q35199181-140CB9E5-EF73-4DEF-A719-C85ABF53817F

Q35199181-1FC8D62D-1983-47E1-B667-ED12D66204AF

Q35199181-2DB8F483-08C9-4F16-ACB1-14F6D21C3F31

Q35199181-3088F809-8B8C-4125-B5E4-DA3F37898EF0

Q35199181-37C0D53B-F327-4699-BA9E-736C342B5D61

Q35199181-38FC8F41-9A7A-499B-83DA-BDF8C654E4A7

Q35199181-438E5F0C-B1FE-4F73-82B9-93F3A71A2289

Q35199181-4CAD2583-F65A-4592-9B51-E21A96ECA0D2

P304

Q35199181-98E4ABF3-E239-4B54-846D-7501744D7AAC

P31

Q35199181-4D50AEC4-F064-4540-BDA3-0A059B4C0EE1

P356

Q35199181-F5D3210C-B200-4361-80C5-ACE39EB3D794

P407

Q35199181-764E253F-3042-4767-9188-4D3816E99F0C

P433

Q35199181-444FAA71-391A-4839-83E1-FF801FAA2E73

P478

Q35199181-79BE00AD-AA23-4EFE-94A0-6A0E73F5633B

P577

Q35199181-0612B415-C7A6-4214-9826-26F311D82015

P698

Q35199181-FBFB5903-C6B6-40A4-9F03-2FBA0F57A18A

P921

Q35199181-D54240DD-887A-41F0-AA69-75D871A34F53

P932

Q35199181-22D0EFD8-02C5-400A-8C1C-B381E638010B

P356

J.CANLET.2008.02.049

P1433

P1476

c-Met gene amplification is as ...... l cancer and liver metastases.

@en

P2093

Alfred T Culliford

http://www.w3.org/2001/XMLSchema#string

Ann Forslund

http://www.w3.org/2001/XMLSchema#string

Chin-Tung Chen

http://www.w3.org/2001/XMLSchema#string

Eleanor Kuntz

http://www.w3.org/2001/XMLSchema#string

Francis Barany

http://www.w3.org/2001/XMLSchema#string

Garrett M Nash

http://www.w3.org/2001/XMLSchema#string

Mark Gimbel

http://www.w3.org/2001/XMLSchema#string

Martin R Weiser

http://www.w3.org/2001/XMLSchema#string

Matthew D'Alessio

http://www.w3.org/2001/XMLSchema#string

Philip B Paty

http://www.w3.org/2001/XMLSchema#string

P2860

Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

c-Met: structure, functions and potential for therapeutic inhibition

Met, metastasis, motility and more

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

Cancer statistics, 2007

Epidermal growth factor receptor mutations in lung cancer

Genetic disease detection and DNA amplification using cloned thermostable ligase.

P304

258-269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CANLET.2008.02.049

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

265

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18395971

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

4367187

http://www.w3.org/2001/XMLSchema#string